Abstracts tagged "longitudinal studies"

Abstract Number: 0347 • ACR Convergence 2021
Longitudinal ANA Titers in SLE and ANA+ Controls
Emily Littlejohn¹, Lingxuan Kong², Kelly Speth², Lu Wang² and Emily Somers², ¹Cleveland Clinic, Cleveland, OH, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Antinuclear or anticellular antibodies (ANAs), are a hallmark of systemic lupus erythematosus (SLE). ANAs are also a marker of subclinical autoimmunity, with ~13% of…
Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
Abstract Number: 0503 • ACR Convergence 2021
18F-fluorodeoxyglucose Positron Emission Tomography as a Predictor of Angiographic Progression of Disease in Large-vessel Vasculitis
Kaitlin Quinn¹, Mark A. Ahlman², Hugh Alessi³, Ashkan Malayeri², Jamie Marko², Elaine Novakovich² and Peter Grayson⁴, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, ²National Institutes of Health, Bethesda, MD, ³National Institutes of Health, Bethesda, Maryland, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: There is limited prospective data characterizing arterial lesions over time in giant cell arteritis (GCA) and Takayasu’s arteritis (TAK), the two main forms of…
Abstract Number: 1800 • ACR Convergence 2021
Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis
Ananta Paine¹, Paul Brookes², Dongmei Li³, Somyaroop Bhattacharya⁴, Maria de la Luz Garcia-Hernandez¹ and Christopher Ritchlin¹, ¹Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ²Department of Pharmacology & Physiology, University of Rochester Medical Center, Rochester, NY, ³Department of Clinical and Translational Research, University of Rochester Medical Center, Rochester, NY, ⁴Division of Neonatology, Department of Pediatrics, University of Rochester, Rochester, NY
Background/Purpose: The transition to psoriatic arthritis (PsA) occurs in 20-30% of psoriasis (Ps) patients, but the mechanisms underlying the emergence of musculoskeletal disease are not…
Abstract Number: 0591 • ACR Convergence 2021
The Temporal Association Between Hospital Admissions, Disease-modifying Anti-rheumatic Drugs Usage and Direct Health Care Costs in Rheumatoid Arthritis Patients
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Australia, ²University of Western Australia, Daglish, Australia, ³University of Western Australia, Nedlands, Perth, Australia
Background/Purpose: Rheumatoid arthritis (RA) carries a substantial burden for patients and society in terms of morbidity, disability, and medical expenses. The Australian Pharmaceutical Benefits Scheme…
Abstract Number: 1912 • ACR Convergence 2021
Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis
Peter Mandl¹, Paul Studenic², Farideh Alasti¹, Rainer Kaltenberger³, Andreas Kerschbaumer¹, Thomas Krennert³, Josef Smolen¹ and Daniel Aletaha⁴, ¹Medical University of Vienna, Vienna, Austria, ²Karolinska Institute; & Medical University of Vienna, Stockholm, Sweden, ³Central Institute for Meteorology and Geodynamics, Vienna, Austria, ⁴Medical University Vienna, Vienna, Austria
Background/Purpose: The notion that weather conditions may influence the symptoms and course of rheumatic and musculoskeletal diseases goes back to ancient times. We aimed to…
Abstract Number: 0781 • ACR Convergence 2021
Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
Suzanne Li¹, Aaron Thammavongxay², Maria Ibarra³, Kathryn Torok⁴, Polly Ferguson⁵, C Egla Rabinovich⁶, Robert Fuhlbrigge⁷, Katie Stewart⁸, Elena Pope⁹, Ronald Laxer¹⁰, Sandy Hong¹¹, Thomas Mason¹², Mara Becker¹³, Gloria Higgins¹⁴, Fatma Dedeoglu¹⁵ and for the CARRA Legacy Registry¹⁶, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, ²Bergen Academies, Hackensack, NJ, ³Children's Mercy Hospital, Kansas City, MO, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Iowa Carver College of Medicine, Iowa City, IA, ⁶Duke Childrens Hospital & Health Center, Durham, NC, ⁷University of Colorado, Denver, CO, ⁸UT Southwestern, Dallas, TX, ⁹Hospital for Sick Kids, Toronto, ON, Canada, ¹⁰SickKids, Toronto, ON, Canada, ¹¹University of Iowa Stead Family Children's Hospital, Iowa City, IA, ¹²Mayo Clinic, Rochester, MN, ¹³Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ¹⁴Ohio State University, Columbus, OH, ¹⁵Boston Children's Hospital, Boston, MA, ¹⁶Childhood Arthritis and Rheumatology Research Alliance, Milwaukee, WI
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…
Abstract Number: 0810 • ACR Convergence 2021
Persistent Disease Activity Impairs Work Productivity and Non-work Activity in Recent Onset Rheumatoid Arthritis
Carol Hitchon¹, Marie-France Valois², Orit Schieir³, Susan Bartlett², Louis Bessette⁴, Gilles Boire⁵, Glen Hazlewood⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin¹⁰, Vivian Bykerk¹¹ and Canadian Early Arthritis Cohort (CATCH) Investigators¹², ¹University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montréal, QC, Canada, ³Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ⁴Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰The Arthritis Program Research Group, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Canadian Early Arthritis Cohort, Toronto, ON, Canada
Background/Purpose: Reduced work and activity productivity are significant contributors to the personal and societal costs associated with rheumatoid arthritis (RA). We sought to describe work…
Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
Abstract Number: 0853 • ACR Convergence 2021
A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap
Craig Willers¹, Tom Lynch¹, Vibhasha Chand², Mohammad Islam³, Marissa Lassere⁴, Helen Keen⁵, Tony Kenna⁶, Susan Lester⁷, Ranjeny Thomas⁸, Premarani Sinnathurai⁹, Mihir Wechalekar¹⁰, Ashley Fletcher¹¹, Daniel Lightowler¹², Sheeraz Mohd¹³, Nishta Ramnoruth¹⁴, Carlee Ruediger¹⁵, Helen Weedon¹⁶ and Lyn March¹⁷, ¹Institute of Bone and Joint Research, Kolling Institute, University of Sydney, St Leonards, Australia, ²Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³Information and Communications Technology, University of Sydney, Sydney, Australia, ⁴St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, ⁵University of Western Australia, Daglish, Australia, ⁶Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, ⁷Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁸University of Queensland, Diamantina Institute, Brisbane, Australia, ⁹Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, ¹⁰Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, ¹¹Cabrini Health, Malvern, Australia, ¹²Medical School, University of Western Australia; Rheumatology Department, Fiona Stanley Hospital, Perth, Australia, ¹³Fiona Stanley Hospital, South Metropolitan Health Services, Perth, Australia, ¹⁴Diamantina Institute, University of Queensland, Brisbane, Australia, ¹⁵University of Adelaide; The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁶Flinders University, Bedford Park, Australia, ¹⁷Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia
Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…
Abstract Number: 0897 • ACR Convergence 2021
Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Tae-Han Lee¹, Bon San Koo², Bora Nam³, Seunghun Lee⁴, Kyung Bin Joo⁴ and Tae-Hwan Kim³, ¹Keimyung University Dongsan Hospital, Daegu, Republic of Korea, ²Inje University Seoul Paik Hospital, Seoul, Republic of Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Hanyang University Hospital, Seoul, Republic of Korea
Background/Purpose: Previous studies investigating the course of spinal structural progression in patients with ankylosing spondylitis (AS) using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)…
Abstract Number: 0932 • ACR Convergence 2021
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay Von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Späthling-Mestekemper⁸, Christoph Kuhn⁹, Fabian Proft¹⁰, Denis Poddubnyy¹¹, Mathias Englbrecht¹² and Wolfgang Vorbrüggen¹³, ¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ²Rhein-Maas Klinikum, Wuerselen, Germany, ³Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁴Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁵Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ⁶rheumapraxis, Osnabrck, Germany, ⁷Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ⁸Rheumapraxis München, München, Germany, ⁹Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹²Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹³Verein zur Förderung der Rheumatologie e.V., Würselen, Germany
Background/Purpose: Increasing immunmodulatory treatment options are available for axial spondyloarthritis. Little is known about sequential treatment in clinical routine.Methods: The pseudonymized RHADAR database (Kleinert, S.…
Abstract Number: 1158 • ACR Convergence 2021
Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up
Kaleb Michaud¹, Sofia Pedro², Victoria Jasion³, Holly Budlong⁴, Jessica Suboticki⁵, Frederick Wolfe⁶ and Patricia Katz⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³AbbVie, Overland Park, KS, ⁴AbbVie, Minneapolis, MN, ⁵AbbVie Inc., North Chicago, IL, ⁶National Data Bank for Rheumatic Diseases, Wichita, KS, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: Treatment options for rheumatoid arthritis (RA) have increased dramatically over the past 15 years. The objective of this study was to investigate whether willingness…
Abstract Number: 1197 • ACR Convergence 2021
Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation
Adelina Plachokova¹, Jill Hadisurya¹, Julia van Bergen² and Rogier Thurlings³, ¹Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, Netherlands, ²Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, ³Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Transversal cohort studies demonstrated a possible association between periodontal disease (PD) and rheumatoid arthritis (RA). However it is unknown how this association evolves during…
Abstract Number: 0143 • ACR Convergence 2021
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Dinesh Khanna¹, Dan Furst², Justin Li³, Qian Meng⁴, Tamara Lesperance⁵, Kenyatta Peoples⁶, Farah Ali⁵, Brian LaMoreaux⁵ and Stephanie Taylor⁷, ¹University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³Trinity Partners, Waltham, MA, ⁴Trinity Life Sciences, Waltham, MA, ⁵Horizon Therapeutics plc, Deerfield, IL, ⁶Horizon Therapeutics plc, Lake Forest, IL, ⁷Horizon Therapeutics plc, Whitehouse Station, NJ
Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…

« Previous Page
1
…
5
6
7
8
9
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].